T-Cell NK-Cell Engaging Bispecific Antibodies Market

Immunotherapy of cancer with T-cells oder NK cells is an area of great interest for the biopharmaceutical industry. Chimeric antigen receptor (CAR) engineered T-cell or NK cells represent one treatment modality under clinical evaluation, but the majority of Big Pharma prefers the engagement of T-cells or NK cells by recombinant monoclonal antibodies as off-the-shelf products. As only a few major pharmaceutical companies have clinically validated in-house bispecific antibody technology, partnering with technology providing companies is of great importance.

T-Cell NK-Cell Engaging Bispecific Antibodies Market contains market size and forecasts of T-Cell & NK-Cell Engaging Bispecific Antibodies in global, including the following market information:

Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Sales, 2017-2022, 2023-2028, (ml)

Global top five T-Cell & NK-Cell Engaging Bispecific Antibodies companies in 2021 (%)

The global T-Cell & NK-Cell Engaging Bispecific Antibodies market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Recombinant Monoclonal Antibodies Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of T-Cell & NK-Cell Engaging Bispecific Antibodies include AbbVie, Astellas Pharma, GEMoaB Monoclonals, Immunocore, Molecular Partners, Roche, AstraZeneca, Merck & Co. and Pfizer, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the T-Cell & NK-Cell Engaging Bispecific Antibodies manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (ml)

Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Segment Percentages, by Type, 2021 (%)

Recombinant Monoclonal Antibodies

In-House Bispecific Antibodies

Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (ml)

Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Segment Percentages, by Application, 2021 (%)

Immunotherapy of Cancer

Clinical Experiment

Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (ml)

Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies T-Cell & NK-Cell Engaging Bispecific Antibodies revenues in global market, 2017-2022 (Estimated), ($ millions)

Key companies T-Cell & NK-Cell Engaging Bispecific Antibodies revenues share in global market, 2021 (%)

Key companies T-Cell & NK-Cell Engaging Bispecific Antibodies sales in global market, 2017-2022 (Estimated), (ml)

Key companies T-Cell & NK-Cell Engaging Bispecific Antibodies sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

AbbVie

Astellas Pharma

GEMoaB Monoclonals

Immunocore

Molecular Partners

Roche

AstraZeneca

Merck & Co.

Pfizer

Eli Lilly

IGM Biosciences

Novartis

BenHealth Biopharmaceuticals

CytomX Therapeutics

Janssen

Lava Therapeutics

MacroGenics

Maverick Therapeutics

VBL Therapeutics

Amgen